The adult data on the use of regional citrate anticoagulation during continuous renal replacement therapy show a decreased risk of bleeding and at the least equivalent circuit survival as compared ...

Pediatr Crit Care Med. 2014;15(5):471-485.

Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected ... beyond 48 hours as well as heparin-tolerant patients at certain ...

"We continue to evaluate and focus on opportunities to support completion of the NEPHRO CRRT study by the end ... who cannot tolerate heparin or are at risk for bleeding. The primary endpoint ...

2-Year U.S. Treasury Note Continuous Contract $102.758-0.055-0.05% 5-Year U.S. Treasury Note Continuous Contract $106.391 0.000 0.00% 10-Year U.S. Treasury Note Continuous Contract $108.938 0.094 ...

requesting a reduction in the number of patients in the NEPHRO CRRT clinical study. A PAS is reviewed by the FDA within 30 days, and its approval by Ascentage Pharma (6855.HK), a global ...

During her time at CNET, Kim Wong-Shing loved demystifying the world of wellness to make it accessible to any reader. She was also passionate about exploring the intersections of health, history ...

38 Larger robust studies comparing these two CRRT modalities are lacking in the literature. Of interest, our critical care standard RRT therapy is now CVVHD with citrate anticoagulation. This would ...

Executive Editor David Carnoy has been a leading member of CNET's Reviews team since 2000. He covers the gamut of gadgets and is a notable reviewer of mobile accessories and portable audio ...

2-Year U.S. Treasury Note Continuous Contract $102.879-0.016-0.02% 5-Year U.S. Treasury Note Continuous Contract $106.539-0.078-0.07% 10-Year U.S. Treasury Note Continuous Contract $109.031-0.203 ...